A small oxazine compound as an anti-tumor agent: A novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-α

Cancer Letters

Volumn 297, Issue 2, 2010, Pages 231-243

  Basappa, ^a,b,d,e   Murugan, Sengottuvelan ^a   Kavitha, Chandagirikoppal V ^c   Purushothaman, Anurag ^b   Nevin, Kottayath G ^a   Sugahara, Kazuyuki ^a,b   Rangappa, Kanchugarakoppal S ^c  

^a HOKKAIDO UNIVERSITY   (Japan)

^b KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF MYSORE   (India)

^d SINGAPORE MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY   (Singapore)

^e BANGALORE UNIVERSITY   (India)

Author keywords

Growth factors; Heparin; Oxazines; Sugar mimetics; Tumor metastases

Indexed keywords

2 (2,6 DIFLUOROPHENYL) 5 (4 METHOXYPHENYL) 1 OXA 3 AZASPIRO[5.5]UNDECANE; ANTINEOPLASTIC AGENT; HEPARIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; 2-(2,6-DIFLUOROPHENYL)-4A,5,6,7,8,8A-HEXAHYDRO-4A-(4-METHOXYPHENYL)-4H-BENZO(E)(1,3)OXAZINE; ANGIOGENESIS INHIBITOR; BENZOXAZINE DERIVATIVE; BETA GLUCURONIDASE; HBEGF PROTEIN, HUMAN; HBEGF PROTEIN, MOUSE; HEPARANASE; PROTEIN BINDING; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; C3H MOUSE; C57BL MOUSE; CELL GROWTH; CELL MOTION; DRUG EFFECTS; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; SECONDARY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZOXAZINES; BONE NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GLUCURONIDASE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; OSTEOSARCOMA; OVARIAN NEOPLASMS; PROTEIN BINDING; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTORS; HEPARIN-BINDING EGF-LIKE GROWTH FACTOR;

MURINAE;

EID: 77956418569     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.016     Document Type: Article

References (42)

1. Henriksson R., Grankvist K. Interactions between anticancer drugs and other clinically used pharmaceuticals. A review. Acta Oncol. 1989, 28:451-462.
2. Weidmann B., Abeles R.H. Mechanism of inactivation of chymotrypsin by 5-butyl-3H-1,3-oxazine-2,6-dione. Biochemistry 1984, 23:2373-2376.
3. Kusakabe Y., Nagatsu J., Shibuya M., Kawaguchi O., Hirose C. Minimycin, a new antibiotic. J. Antibiot. 1972, 25:44-47.
4. Moorman A.R., Abeles R.H. New class of serine protease inactivators based on isatoic anhydride. J. Am. Chem. Soc. 1982, 104:6785-6786.
5. Mundhenke C., Meyer K., Drew S., Friedl A. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am. J. Pathol. 2002, 160:185-194.
6. Iozzo R.V., San Antonio J.D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 2001, 108:349-355.
7. Chu C.L., Goerges A.L., Nugent M.A. Identification of common and specific growth factor binding sites in heparan sulfate proteoglycans. Biochemistry 2005, 44:12203-12213.
8. Vlodavsky I., Bar-Shavit R., Ishai-Michaeli R., Bashkin P., Fuks Z. Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism?. Trends Biochem. Sci. 1991, 16:268-271.
9. Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., Bitan M., Pappo O., Peretz T., Michal I., Spector L., Pecker I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 1999, 5:793-802.
10. Goldshmidt O., Zcharia E., Abramovitch R., Metzger S., Aingorn H., Friedmann Y., Schirrmacher V., Mitrani E., Vlodavsky I. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc. Natl. Acad. Sci. USA 2002, 99:10031-10036.
11. Hulett M.D., Freeman C., Hamdorf B.J., Baker R.T., Harris M.J., Parish C.R. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 1999, 5:803-809.
12. Sasisekharan R., Shriver Z., Venkataraman G., Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer 2002, 2:521-528.
13. Ishida K., Wierzba M.K., Teruya T., Simizu S., Osada H. Novel heparan sulfate mimetic compounds as antitumor agents. Chem. Biol. 2004, 11:367-377.
14. Jayne D.G., Perry S.L., Morrison E., Farmery S.M., Guillou P.J. Activated mesothelial cells produce heparin-binding growth factors: implications for tumor metastases. Br. J. Cancer 2000, 82:1233-1238.
15. Tammela T., Zarkada G., Wallgard E., Murtomäki A., Suchting S., Wirzenius M., Waltari M., Hellström M., Schomber T., Peltonen R., Freitas C., Duarte A., Isoniemi H., Laakkonen P., Christofori G., Ylä-Herttuala S., Shibuya M., Pytowski B., Eichmann A., Betsholtz C., Alitalo K. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454:656-660.
16. 121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparin sulfates for efficient binding to the VEGF receptors of human melanoma cells. J. Biol. Chem. 1995, 270:11322-11326.
17. Miyamoto S., Hirata M., Yamanaki A., Kageyama T., Hasuwa H., Mizushima H., Tanaka Y., Yagi H., Sonoda K., Kai M., Kanoh H., Nakano H., Mekada E. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res. 2004, 64:5720-5727.
18. Ramnarain D.B., Park S., Lee D.Y., Hatanpaa K.J., Scoggin S.O., Out H., Libermann T.A., Raisanen J.M., Ashfaq R., Wong E.T., Wu J., Elliott R., Habib A.A. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res. 2006, 66:867-874.
19. Kim J., Jahng W.J., Di Vizio D., Lee J.S., Jhaveri R., Rubin M.A., Shisheva A., Freeman M.R. The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus. Cancer Res. 2007, 67:9229-9237.
20. Miyamoto S., Yagi H., Yotsumoto F., Kawarabayashi T., Mekada E. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci. 2006, 97:341-347.
21. Egberts J.H., Cloosters V., Noack A., Schniewind B., Thon L., Klose S., Kettler B., von Forstner C., Kneitz C., Tepel J., Adam D., Wajant H., Kalthoff H., Trauzold A. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008, 68:1443-1450.
22. Lee C.M., Tanaka T., Murai T., Kondo M., Kimura J., Su W., Kitagawa T., Ito T., Matsuda H., Miyasaka M. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res. 2002, 62:4282-4288.
23. Fidler I.J., Nicolson G.L. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J. Natl. Cancer Inst. 1976, 57:1199-1202.
24. Basappa, Murugan S., Sugahara K.N., Lee C.M., ten Dam G.B., van Kuppevelt T.H., Miyasaka M., Yamada S., Sugahara K. Involvement of chondroitin sulfate E in the liver tumor focal formation of murine osteosarcoma cells. Glycobiology 2009, 19:735-742.
25. Xing J.Z., Zhu L., Jackson J.A., Gabos S., Sun X.J., Wang X.B., Xu X. Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem. Res. Toxicol. 2005, 18:154-161.
26. Okada Y., Yamada S., Toyoshima M., Dong J., Nakajima M., Sugahara K. Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence. J. Biol. Chem. 2002, 277:42488-42495.
27. Takahashi H., Ebihara S., Okazaki T., Suzuki S., Asada M., Kubo H., Sasaki H. Design and synthesis of a heparanase inhibitor with pseudodisaccharide structure. Lung Cancer 2004, 45:207-214.
28. Fernández C., Hattan C.M., Kerns R.J. Semi-synthetic heparin derivatives: chemical modifications of heparin beyond chain length, sulfate substitution pattern and N-sulfo/N-acetyl groups. Carbohyd. Res. 2006, 341:1253-1265.
29. Miao H.Q., Elkin M., Aingorn E., Ishai-Michaeli R., Stein C.A., Vlodavsky I. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int. J. Cancer 1999, 83:424-431.
30. Saiki I., Murata J., Nakajima M., Tokura S., Azuma I. Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells. Cancer Res. 1990, 50:3631-3637.
31. Ferro V., Dredge K., Liu L., Hammond E., Bytheway I., Li C., Johnstone K., Karoli T., Davis K., Copeman E., Gautam A. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin. Thromb. Hemost. 2007, 33:557-568.
32. Takahashi S., Kuzuhara H., Nakajima M. Design and synthesis of a heparanase inhibitor with pseudodisaccharide structure. Tetrahedron 2001, 57:6915-6926.
33. Basappa, Kavitha C.V., Rangappa K.S. Simple and an efficient method for the synthesis of 1-[2-dimethylamino-1-(4-methoxy-phenyl)-ethyl]-cyclohexanol hydrochloride: (+/-) venlafaxine racemic mixtures. Bioorg. Med. Chem. Lett. 2004, 14:3279-3281.
34. Kavitha C.V., Lakshmi S., Basappa, Mantelingu K., Sridhar M.A., Prasad J., Rangappa K.S. Synthesis and molecular structure analysis of venlafaxine intermediate and its analog. J. Chem. Cryst. 2006, 35:957-963.
35. Saito A., Kawai K., Takayama H., Sudo T., Osada H. Improvement of photoaffinity SPR imaging platform and determination of binding site of p62/SQSTM1 to p38 MAP kinase. Chem. Asian J. 2008, 3:1607-1612.
36. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control Release 2008, 132:171-183.
37. Waldman T., Zhang Y., Dillehay L., Yu J., Kinzler K., Vogelstein B., Williams Cell-cycle arrest versus cell death in cancer therapy. J. Nat. Med. 1997, 3:1034-1036.
38. Chambers A.F. The metastatic process: basic research and clinical implications. Oncol. Res. 1999, 11:161-168.
39. Pikas D.S., Li J.P., Vlodavsky I., Lindahl U. Substrate specificity of heparanases from human hepatoma and platelets. J. Biol. Chem. 1998, 273:18770-18777.
40. Dhanabal M., Jeffers M., Larochelle W.J. Anti-angiogenic therapy as a cancer treatment paradigm. Curr. Med. Chem. Anticancer Agents 2005, 5:115-130.
41. Zhu Z., Witte L. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest. New Drugs 1999, 17:195-212.
42. Zhao H., Liu H., Chen Y., Xin X., Li J., Hou Y., Zhang Z., Zhang X., Xie C., Geng M., Ding J. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res. 2006, 66:8779-8887.